320 Soquel Way
Sunnyvale, CA 94085
United States
650 226 0120
https://www.biocardia.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 16
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Peter A. Altman Ph.D. | CEO, President & Director | 515.51k | N/D | 1967 |
Mr. David McClung | Chief Financial Officer | 370.86k | N/D | 1963 |
Mr. Edward M. Gillis | Senior Vice President of Devices | 263.1k | N/D | 1962 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.
La calificación ISS Governance QuickScore de BioCardia, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.